A population‐based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer

Abstract

BACKGROUND: Sunitinib has replaced interferon (IFN) as a first-line standard of care in the treatment of metastatic renal cell carcinoma (RCC). This study aimed to determine overall survival and to confirm effectiveness in a population that includes poor prognosis patients. RESULTS: There were 131 and 69 patients in the IFN and sunitinib groups, respectively. The median followup of those still alive was 12.6 months. The median age (62 vs 63 years; P ¼ .41), Memorial Sloan Kettering Cancer Center (MSKCC) prognostic criteria (poor in 19% vs 30%; P ¼ .41), and proportion with >1 metastasis (53% vs 62%; P ¼ .21) were similar between the IFN and sunitinib groups, respectively. The median survival of the IFN and sunitinib groups was 8.7 and 17.3 months, respectively (log-rank P ¼ .004). The median survival of patients with favorable, intermediate, and poor MSKCC prognostic profiles in the IFN group was 22.9, 8.7, and 4

Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008)

“…In conclusion, the results from our retrospective study are encouraging, consistent with findings from previously reported real-life register studies (Heng et al , 2009; Shek et al , 2012), and would appear to justify the optimism stemming from use of targeted agents. In addition, this provides verification of treatment benefit in a general population beyond clinical trials – evidence that is sparse in the mRCC literature.…”

Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008)

“…In conclusion, the results from our retrospective study are encouraging, consistent with findings from previously reported real-life register studies (Heng et al , 2009; Shek et al , 2012), and would appear to justify the optimism stemming from use of targeted agents. In addition, this provides verification of treatment benefit in a general population beyond clinical trials – evidence that is sparse in the mRCC literature.…”

Patterns of care for metastatic renal cell carcinoma in A ustralia

“…This is consistent with the survival advantage for sunitinib over interferon in a group of poor‐risk patients reported by Heng et al. . The decision to not reimburse sunitinib for poor‐risk patients was based upon minimal data supporting such a strategy in the pivotal registration study where Motzer et al.…”

Logical Imputation to Optimize Prognostic Risk Classification in Metastatic Renal Cell Cancer

“…For example, corrected serum calcium was missing for 45% of the Spanish patients and 16% of the Dutch patients. Indeed, variable frequen-cies of missing data on MSKCC and IMDC model parameters are also seen in other studies [6,7,20]. Using logical imputation, we were able to classify ∼17% of EuroTARGET patients with at least one missing value to the poor or intermediate risk group.…”

Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008)

“…In conclusion, the results from our retrospective study are encouraging, consistent with findings from previously reported real-life register studies (Heng et al , 2009; Shek et al , 2012), and would appear to justify the optimism stemming from use of targeted agents. In addition, this provides verification of treatment benefit in a general population beyond clinical trials – evidence that is sparse in the mRCC literature.…”

Patterns of care for metastatic renal cell carcinoma in A ustralia

“…This is consistent with the survival advantage for sunitinib over interferon in a group of poor‐risk patients reported by Heng et al. . The decision to not reimburse sunitinib for poor‐risk patients was based upon minimal data supporting such a strategy in the pivotal registration study where Motzer et al.…”

Logical Imputation to Optimize Prognostic Risk Classification in Metastatic Renal Cell Cancer

“…For example, corrected serum calcium was missing for 45% of the Spanish patients and 16% of the Dutch patients. Indeed, variable frequen-cies of missing data on MSKCC and IMDC model parameters are also seen in other studies [6,7,20]. Using logical imputation, we were able to classify ∼17% of EuroTARGET patients with at least one missing value to the poor or intermediate risk group.…”

Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008)

“…In conclusion, the results from our retrospective study are encouraging, consistent with findings from previously reported real-life register studies (Heng et al , 2009; Shek et al , 2012), and would appear to justify the optimism stemming from use of targeted agents. In addition, this provides verification of treatment benefit in a general population beyond clinical trials – evidence that is sparse in the mRCC literature.…”

Patterns of care for metastatic renal cell carcinoma in A ustralia

“…This is consistent with the survival advantage for sunitinib over interferon in a group of poor‐risk patients reported by Heng et al. . The decision to not reimburse sunitinib for poor‐risk patients was based upon minimal data supporting such a strategy in the pivotal registration study where Motzer et al.…”

Logical Imputation to Optimize Prognostic Risk Classification in Metastatic Renal Cell Cancer

“…For example, corrected serum calcium was missing for 45% of the Spanish patients and 16% of the Dutch patients. Indeed, variable frequen-cies of missing data on MSKCC and IMDC model parameters are also seen in other studies [6,7,20]. Using logical imputation, we were able to classify ∼17% of EuroTARGET patients with at least one missing value to the poor or intermediate risk group.…”